

Glymphatic System Dysfunction In Alzheimer’s Disease: Astrocytic Stress Signaling, Impaired Clearance, And Protein Aggregation

Harsimrat Singh Kooner¹, BS, OMS-II, Deepesh Khanna¹, Ph.D., M.B.B.S., M.P.H., M.B.A, M.S., C.P.H.

¹ Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Clearwater, FL, 33759, USA



Introduction

- Alzheimer’s disease (AD) is a progressive neurodegenerative disorder marked by **amyloid- β plaques**, **tau tangles**, **synaptic dysfunction**, and **neuronal loss**.
- The glymphatic system mediates **CSF–ISF** exchange to remove metabolic waste, including **A β** and **tau**.
- Disruption of glymphatic clearance can lead to **waste accumulation**, **neuroinflammation**, and **synaptic impairment**.
- Understanding glymphatic dysfunction is essential for identifying upstream drivers and novel therapeutic targets in AD.

Objective

- Evaluate glymphatic system dysfunction as an **active** and **modifiable** driver of AD pathogenesis.
- Emphasize **astrocytic** stress signaling, **AQP4** polarity loss, and impaired **CSF–ISF** exchange.
- Examine how **sleep/circadian** disruption and **vascular** dysfunction amplify clearance failure and protein aggregation.
- Integrate **astrocytic**, **vascular**, and **immune** mechanisms to define therapeutic targets for intervention.

Methods

- Database: PubMed.
- Search terms: “**Glymphatic System**” AND “**Alzheimer’s Disease**,” refined with “**Astrocytes**.”
- Timeframe: 2015–2026.
- Initial search: **603** articles; refined search: 106 **astrocyte-focused** articles.
- Inclusion: human/animal studies on **astrocytes**, **AQP4 polarity**, **glymphatic function**, **sleep/circadian**, **vascular**, **A β /tau**.
- Final included studies: n = **36**.

Results: Key Findings

- Glymphatic dysfunction **reduces** CSF–ISF exchange and **limits** clearance of **amyloid- β** , **tau**, and other metabolic waste.
- Astrocyte **PERK–eIF2 α** stress signaling and inflammation disrupt **AQP4** polarity and **perivascular** end-feet organization.
- Sleep/circadian disruption and vascular dysfunction impair **glymphatic flow** and solute clearance.
- A β /tau **accumulation** further worsens astrocytic and vascular pathology, creating a **self-amplifying cycle**.

Glymphatic Dysfunction as an Active Driver

- Clearance failure increases **residence time** of soluble A β and tau, promoting **oligomerization** and glial activation.
- A self-amplifying cycle develops leading to impaired **clearance** → protein **accumulation** → **neuroinflammation** → synaptic **degeneration**.
- Acts as a mechanistic bridge linking proteostasis failure, neuroinflammation, and synaptic dysfunction in AD.

Astrocytic Stress Signaling and AQP4 Mis-localization

- Astrocytic stress activates **PERK–eIF2 α** and inflammatory pathways.
- Disruption of cytoskeletal/trafficking pathways mislocalizes AQP4 from perivascular end-feet.
- Elevated cytokines, including **TNF- α** , **IL-1 β** , and **ROS**, sustain astrocytic reactivity and impair glymphatic function.


Sleep, Circadian Rhythm, and Vascular Dynamics

- Sleep enhances **glymphatic flow** and **CSF influx**; sleep loss reduces clearance.
- Circadian misalignment alters astrocytic AQP4 **expression** and **polarization**.
- Vascular dysfunction, including **pulsatility**, **endothelial** function, and **BBB** disruption, disrupts perivascular driving forces essential for glymphatic flow.

A β /Tau Aggregation and Synaptic Degeneration

- Reduced clearance prolongs **A β** and **tau** residence in the brain.
- Promotes oligomerization, **neurotoxicity**, and tau hyperphosphorylation.
- Leads to synaptic loss, dendritic spine **reduction**, and cognitive decline.

Figure 1. Mechanistic Cascade of Glymphatic Clearance Failure in Alzheimer’s Disease.



AQP4 Polarity and Perivascular Unit Dysfunction

- Loss of perivascular AQP4 localization weakens **CSF–ISF** exchange and glymphatic flow.
- Endothelial dysfunction and reduced arterial pulsatility further impair **solute clearance**.
- Perivascular **inflammation** and BBB **leakage** disrupt the neurovascular–glymphatic interface.
- Altered CSF AQP4 levels reflect downstream effects of upstream astrocytic and vascular injury.

Conclusions

- Glymphatic clearance failure is an **active** contributor to AD progression, not a passive consequence of aging or neurodegeneration.
- Astrocytic stress**, **AQP4 polarity loss**, **sleep/circadian disruption**, and **vascular dysfunction** converge to impair clearance and promote A β /tau aggregation.
- Targeting glymphatic pathways offers a promising therapeutic strategy to slow or prevent AD.
- Future studies should validate **biomarkers** and test interventions that restore glymphatic function.

Therapeutic Implications of Targeting Glymphatic and Intracranial Lymphatic Systems

- Therapeutic strategies: pharmacologic agents (e.g., resveratrol, **melatonin**), exercise, and optimized sleep may enhance glymphatic flow.
- Restoring AQP4 polarity alone may be **insufficient** if vascular/meningeal lymphatic drainage remains impaired.
- Emerging targets: astrocytic **PERK–eIF2 α** signaling, **anti-inflammatory** modulators, and AQP4 trafficking.
- Current evidence is promising but largely preclinical; longitudinal human studies are needed to determine directionality and clinical efficacy.

Selected References



Author Contact

